| Bioactivity | CDK1/Cyc B-IN-1 (Compound 5) is a selective CDK1/Cyc B complex inhibitor with an IC50 of 97 nM. CDK1/Cyc B-IN-1 triggers apoptosis and G2/M cell cycle arrest. CDK1/Cyc B-IN-1 shows broad-spectrum cytotoxic action against cancer cell lines[1]. |
| Invitro | CDK1/Cyc B-IN-1 (Compound 5) shows cytotoxic activity with IC50 values of 5.33 ± 0.69 µM and 21.69 ± 1.04 µM against HCT-116 and WI-38, respectively[1]. |
| Name | CDK1/Cyc B-IN-1 |
| CAS | 2459916-56-2 |
| Formula | C14H12ClN3O2S2 |
| Molar Mass | 353.85 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Mohamed SH, et al. An investigative study of antitumor properties of a novel thiazolo[4,5-d]pyrimidine small molecule revealing superior antitumor activity with CDK1 selectivity and potent pro-apoptotic properties. Bioorg Med Chem. 2020 Sep 1;28(17):11563 |
CDK1/Cyc B-IN-1
CAS: 2459916-56-2 F: C14H12ClN3O2S2 W: 353.85
CDK1/Cyc B-IN-1 (Compound 5) is a selective CDK1/Cyc B complex inhibitor with an IC50 of 97 nM. CDK1/Cyc B-IN-1 triggers
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.